HS235

• Financing led by Frazier Life Sciences with participation from new investors including Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors and Columbia Threadneedle

Montreal, QC, Canada (Nov 26, 2024)  – 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced the closing of an oversubscribed $53 million Series C financing. The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.

The Series C financing was led by Frazier Life Sciences with participation from additional new investors that included Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, Columbia Threadneedle, as well as from existing investors VenBio, Surveyor Capital, Logos Capital and Marshall Wace.

“We are delighted to close this Series C financing, which brings multiple new marquee healthcare investors into our cap table,” said Ilia A. Tikhomirov, CEO of 35Pharma. “This financing is intended to support initial clinical proof-of-concept studies for HS135 in pulmonary hypertension, as well as advance HS235 – our candidate for the treatment of HFpEF and obesity – through a Phase 1 proof-of-biology trial in obese and overweight healthy volunteers.”

“Targeting Activin- and GDF-mediated signaling has emerged as an important therapeutic approach across cardiometabolic and pulmonary disease,” said Kevin Li, M.D., Principal at Frazier Life Sciences. “Drawing from its deep expertise in TGF-beta biology and protein engineering, 35Pharma has developed two clinical-stage assets with the potential for best-in-class efficacy and safety. Frazier Life Sciences is pleased to support the team in advancing their pipeline through the clinic, and toward the goal of transforming the standard of care in pulmonary hypertension, obesity, and heart failure.”

About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology, combined with superior protein engineering, to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands, while sparing beneficial homeostatic ligands. For more information, please visit www.35pharma.com

Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com

• Oral presentation will feature HS235, the Company’s Phase 1 Activin and GDF inhibitor for cardiometabolic disease and obesity
• HS235 improved body composition, and rescued left ventricular function and exercise capacity in a murine obese HFpEF model

Montreal, QC, Canada (Nov 03, 2024)  – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at ObesityWeek® 2024 in San Antonio, TX, USA (Nov 3-6, 2024).

HS235 is an Fc-fused ligand trap that selectively and potently neutralizes pathological Activins and growth differentiation factors (GDFs). The Company has recently been cleared to commence Phase 1 clinical testing of HS235 in overweight and obese healthy subjects, and anticipates sharing initial data from this trial during the second half of 2025. 

During an oral presentation at Obesity Week 2024, 35Pharma Chief Scientific Officer Maureen O’Connor will share pre-clinical data with HS235 demonstrating its dual metabolic and cardiac activity in a murine model of obese Heart Failure with preserved Ejection Fraction (HFpEF). 

In this heart failure model, HS235 treatment positively impacted both cardiac function and metabolic health. Specifically, HS235 administration resulted in: 

• decrease in fat mass, including pericardial fat
• increase in muscle mass
• rescue of left ventricular function
• reduction of circulating NT-proBNP, a biomarker of heart failure
• return of exercise capacity to the levels of lean control

Details of the upcoming presentation at ObesityWeek® are as follows:

Title: HS235, a Novel Activin and GDF Ligand Trap, Is Efficacious in a Model of Obesity-Related HFpEF (Oral-030)

Session: Corporate Orals Session 1

Date & Time: November 4th, 2024, 8:30 AM – 8:45 AM

Location: Henry B. González Convention Center, San Antonio, TX, Room 207

About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company focused on the design and development of best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for Pulmonary Hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands while sparing beneficial homeostatic ligands.

Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com

For more information, please visit www.35pharma.com